CU20170137A7 - Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas - Google Patents

Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas

Info

Publication number
CU20170137A7
CU20170137A7 CU2017000137A CU20170137A CU20170137A7 CU 20170137 A7 CU20170137 A7 CU 20170137A7 CU 2017000137 A CU2017000137 A CU 2017000137A CU 20170137 A CU20170137 A CU 20170137A CU 20170137 A7 CU20170137 A7 CU 20170137A7
Authority
CU
Cuba
Prior art keywords
ganglioside
adjuvants
nano
synthetic variants
vaccines
Prior art date
Application number
CU2017000137A
Other languages
English (en)
Other versions
CU24534B1 (es
Inventor
Báez Gretchen Bergado
García Lisset Chao
Rodríguez Mabel Cruz
Gómez Audry Fernández
Molina Luis Fernández
Suárez Narjara González
Fernández Diana Rosa Hernández
BARRANCO Jesús Arturo JUNCO
López Miguel Antonio López
Vargas Ángel Alexis Manso
Pardillo Circe Mesa
Martínez Dayana Pérez
Ramírez Belinda Sánchez
Murguía Blanca Idelmis Tolón
Bencomo Vicente Guillermo Verez
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2017000137A priority Critical patent/CU24534B1/es
Priority to NZ764565A priority patent/NZ764565B2/en
Priority to KR1020207016172A priority patent/KR102728174B1/ko
Priority to EA202091116A priority patent/EA202091116A1/ru
Priority to AU2018359358A priority patent/AU2018359358B2/en
Priority to US16/760,954 priority patent/US11806396B2/en
Priority to CN201880071890.1A priority patent/CN111295200B/zh
Priority to BR112020008668-1A priority patent/BR112020008668A2/pt
Priority to MYPI2020002141A priority patent/MY204283A/en
Priority to EP18822259.0A priority patent/EP3711775A1/en
Priority to JP2020525926A priority patent/JP7332592B2/ja
Priority to PCT/CU2018/050003 priority patent/WO2019086056A1/es
Priority to CA3079105A priority patent/CA3079105A1/en
Priority to SG11202004180SA priority patent/SG11202004180SA/en
Priority to MX2020004644A priority patent/MX2020004644A/es
Priority to TW107137740A priority patent/TWI719351B/zh
Priority to ARP180103229A priority patent/AR114139A1/es
Publication of CU20170137A7 publication Critical patent/CU20170137A7/es
Priority to CONC2020/0006548A priority patent/CO2020006548A2/es
Priority to ZA2020/03218A priority patent/ZA202003218B/en
Publication of CU24534B1 publication Critical patent/CU24534B1/es
Priority to US18/375,788 priority patent/US12280109B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>Esta invención describe Ia forma de obtener adyuvantes nano-particulados basados en diferentes variantes sintéticas del gangliósido GM3. En dependencia de Ia estructura fina del ácido graso presente en el ceramido del GM3 sintético, se pueden obtener adyuvantes que sirven para estimular específica y especializadamente Ia respuesta inmune humoral o Ia celular contra antígenos acompañantes. Particularmente, esta invención provee composiciones vacunales inmunogénicas que comprenden péptidos, polipéptidos o proteínas y las antes mencionadas nano-particulas, que se forman mediante Ia dispersión de proteínas hidrofóbicas del complejo de membrana externa (CPME) de Ia bacteria Neisseria meningitidis con variantes totalmente sintéticas del ganglioside GM3.</p>
CU2017000137A 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 CU24534B1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CU2017000137A CU24534B1 (es) 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
EP18822259.0A EP3711775A1 (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
CA3079105A CA3079105A1 (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
EA202091116A EA202091116A1 (ru) 2017-11-06 2018-10-24 Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинах
AU2018359358A AU2018359358B2 (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
US16/760,954 US11806396B2 (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
CN201880071890.1A CN111295200B (zh) 2017-11-06 2018-10-24 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
BR112020008668-1A BR112020008668A2 (pt) 2017-11-06 2018-10-24 nanopartículas que contêm variantes sintéticas de gangliosídeo gm3 como adjuvantes em vacinas
MYPI2020002141A MY204283A (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
NZ764565A NZ764565B2 (en) 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
JP2020525926A JP7332592B2 (ja) 2017-11-06 2018-10-24 ワクチンアジュバントとしての、ｇｍ３ガングリオシドの合成バリアントを含有するナノ粒子
PCT/CU2018/050003 WO2019086056A1 (es) 2017-11-06 2018-10-24 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas
KR1020207016172A KR102728174B1 (ko) 2017-11-06 2018-10-24 백신 보조제로서 gm3 강글리오시드의 합성 변이체를 포함하는 나노입자
SG11202004180SA SG11202004180SA (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
MX2020004644A MX2020004644A (es) 2017-11-06 2018-10-24 Nano-particulas que contienen variantes sinteticas del gangliosido gm3 como adyuvantes en vacunas.
TW107137740A TWI719351B (zh) 2017-11-06 2018-10-25 於疫苗中作為佐劑的包含ｇｍ３神經節苷脂的合成變體之奈米粒子
ARP180103229A AR114139A1 (es) 2017-11-06 2018-11-06 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas
CONC2020/0006548A CO2020006548A2 (es) 2017-11-06 2020-05-28 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas
ZA2020/03218A ZA202003218B (en) 2017-11-06 2020-05-29 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
US18/375,788 US12280109B2 (en) 2017-11-06 2023-10-02 Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2017000137A CU24534B1 (es) 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Publications (2)

Publication Number Publication Date
CU20170137A7 true CU20170137A7 (es) 2019-06-04
CU24534B1 CU24534B1 (es) 2021-07-02

Family

ID=64745822

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000137A CU24534B1 (es) 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Country Status (18)

Country Link
US (2) US11806396B2 (es)
EP (1) EP3711775A1 (es)
JP (1) JP7332592B2 (es)
KR (1) KR102728174B1 (es)
CN (1) CN111295200B (es)
AR (1) AR114139A1 (es)
AU (1) AU2018359358B2 (es)
BR (1) BR112020008668A2 (es)
CA (1) CA3079105A1 (es)
CO (1) CO2020006548A2 (es)
CU (1) CU24534B1 (es)
EA (1) EA202091116A1 (es)
MX (1) MX2020004644A (es)
MY (1) MY204283A (es)
SG (1) SG11202004180SA (es)
TW (1) TWI719351B (es)
WO (1) WO2019086056A1 (es)
ZA (1) ZA202003218B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU24637B1 (es) 2019-12-24 2022-12-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen
CU24705B1 (es) 2020-10-22 2024-06-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1
CN121130071A (zh) * 2025-11-17 2025-12-16 重庆市畜牧科学院 一种含有免疫佐剂的多肽纳米颗粒疫苗及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
US7776346B2 (en) 2003-05-22 2010-08-17 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal product compositions comprising structured benefit agent premix or delivery vehicle
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
CU23739A1 (es) * 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CU24299B1 (es) 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Also Published As

Publication number Publication date
US20240131152A1 (en) 2024-04-25
JP2021501792A (ja) 2021-01-21
US12280109B2 (en) 2025-04-22
US11806396B2 (en) 2023-11-07
TW201927804A (zh) 2019-07-16
CO2020006548A2 (es) 2020-08-21
US20200268878A1 (en) 2020-08-27
CU24534B1 (es) 2021-07-02
MY204283A (en) 2024-08-21
EP3711775A1 (en) 2020-09-23
KR102728174B1 (ko) 2024-11-11
WO2019086056A1 (es) 2019-05-09
KR20200086315A (ko) 2020-07-16
AU2018359358A1 (en) 2020-06-11
CN111295200B (zh) 2025-05-16
NZ764565A (en) 2024-02-23
EA202091116A1 (ru) 2020-09-24
AR114139A1 (es) 2020-07-29
JP7332592B2 (ja) 2023-08-23
BR112020008668A2 (pt) 2020-10-06
MX2020004644A (es) 2020-07-24
AU2018359358B2 (en) 2022-08-04
CA3079105A1 (en) 2019-05-09
TWI719351B (zh) 2021-02-21
CN111295200A (zh) 2020-06-16
SG11202004180SA (en) 2020-06-29
ZA202003218B (en) 2022-05-25

Similar Documents

Publication Publication Date Title
CO2020006548A2 (es) Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas
CR20200409A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
MX386142B (es) COMPOSICIONES INMUNOGÉNICAS PARA EL CORONAVIRUS DEL SÍNDROME RESPIRATORIO DE ORIENTE MEDIO (MERS-CoV) Y SUS USOS.
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX2023002858A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
UY31942A (es) Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones.
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
AR100745A1 (es) Nanopartículas de quitosano cargadas con antígeno para inmunoterapia
CY1124388T1 (el) Εμβολιο για ανοσοεξασθενημενους δεκτες
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
MX2019006104A (es) Conjugados inmunogenicos y uso de los mismos.
MA40624A (fr) Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
IN2014CN00547A (es)
MX361804B (es) Vacunas genéticas contra el virus hendra y el virus nipah.
CL2014001126A1 (es) Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
RU2010108567A (ru) Стеклоиономерный цемент с добавлением наночастиц кремния
NZ764565B2 (en) Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
CO6592019A2 (es) Vacuna biológica autóloga contra el cancér
BR102014032315A8 (pt) Proteína antifungica: biomolécula recombinante na imunoterapia de doenças de hipersensibilidade e infecções bacterianas e parasitárias